Jupiter Research Capital (Asia) Ltd’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-13,649
Closed -$231K – 967
2026
Q2
$231K Sell
13,649
-20,419
-60% -$286K 0.03% 608
2026
Q1
$437K Buy
+34,068
New +$434K 0.05% 433

Other funds holding NTLA

Jupiter Research Capital (Asia) Ltd's NTLA Position: Q3 2026 in Review

Jupiter Research Capital (Asia) Ltd sold out of Intellia Therapeutics (NTLA) in Q3 2026, closing a stake of 13,649 shares — an estimated $231K sold.

Jupiter Research Capital (Asia) Ltd first reported a position in NTLA in Q1 2026 and held it in 2 quarters. The position peaked at $437K in Q1 2026. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • Jupiter Research Capital (Asia) Ltd reported no remaining Intellia Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Jupiter Research Capital (Asia) Ltd sold 13,649 Intellia Therapeutics shares in Q3 2026, an estimated $231K.
  • Jupiter Research Capital (Asia) Ltd first reported a position in Intellia Therapeutics in Q1 2026 and held it in 2 quarters.
  • Jupiter Research Capital (Asia) Ltd's Intellia Therapeutics position peaked at $437K in Q1 2026.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Jupiter Research Capital (Asia) Ltd's 13F filing for Q3 2026, filed 16 Nov 2026.